(CAPR) to Hold Third Quarter 2014 Business Update Conference Call

LOS ANGELES, Oct. 31, 2014 — Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Company management will hold a conference call to discuss third quarter 2014 business highlights on Wednesday, November 12, 2014, at 4:30 p.m. ET.

On the call, Dr. Linda Marbán, Chief Executive Officer, will review Capricor’s recent accomplishments, provide an update on the clinical development program of the Company’s lead product candidate, CAP-1002, and discuss other Company updates.

Participants can register for the call and webcast via the following link: https://prismdigitalmedia.cwebcast.com/ses/5bIRxAY9rhdWBimYPQBW9A~~. Once registered for the call, interested parties will receive the conference call dial-in information. An archived version of the webcast will remain on the Company’s Investors page at http://www.capricor.com.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on August 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

CONTACT: For more information, please contact:

         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         +1-310-358-3200
         abergmann@capricor.com

         ProActive Capital Group
         Kirin Smith, COO
         +1-646-863-6519
         ksmith@ProActiveCapital.com
         www.ProActiveCapital.com

(ARCW) CEO Featured Panelist at “Make it in America”

DELAND, Fla., Oct. 31, 2014  — ARC Group Worldwide, Inc. (NASDAQ: ARCW), a leading global provider of advanced manufacturing and 3D printing solutions, today announced that its CEO, Jason Young, will be a featured panelist at “Make it in America”, an event focused on the resurgence of U.S. manufacturing. Corridor Capital is hosting the event in Los Angeles on November 4, 2014. Mr. Young will be joining a panel of experts from the Milken Institute, McKinsey, Oaktree Capital and The National Association of Manufacturers to discuss the drivers of the new American manufacturing sector. For more information on the sold-out event, please visit www.make-it-in-america.org.

About ARC Group Worldwide, Inc.

ARC Group Worldwide is a leading global advanced manufacturing and 3D printing service provider.  Founded in 1987, the Company offers its customers a compelling portfolio of advanced manufacturing technologies and cutting-edge capabilities to improve the efficiency of traditional manufacturing processes and accelerate their time to market. In addition to being a world leader in metal injection molding (“MIM”), ARC has significant expertise in 3D printing and imaging, materials science, advanced tooling, automation, machining, stamping, plastic injection molding, lean manufacturing, and robotics. For more information about ARC Group Worldwide, please visit www.ArcGroupWorldwide.com, or its operating subsidiaries at www.3DMaterialTechnologies.com, www.AFTmim.com, www.AFTmimHU.com, www.ARCmim.com, www.ArcWireless.net, www.ATCmold.com, www.FloMet.com, www.GeneralFlange.com, www.Injectamax.com, www.kecycorporation.com, www.TeknaSeal.com, and www.ThixoWorks.com.

IMPORTANT INFORMATION

This press release may contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are based on ARC’s current expectations, estimates and projections about future events. These include, but are not limited to, statements, if any, regarding business plans, pro-forma statements and financial projections, ARC’s ability to expand its services and realize growth. These statements are not historical facts or guarantees of future performance, events or results. Such statements involve potential risks and uncertainties, and the general effects of financial, economic, and regulatory conditions affecting our industries. Accordingly, actual results may differ materially. ARC does not have any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For additional factors that may affect future results, please see filings made by ARC with the Securities and Exchange Commission (“SEC”), including its Form 10-K for the fiscal year ended June 30, 2013 and Form 10-Q for the period ended March 30, 2014, as well as current reports on Form 8-K filed from time-to-time with the SEC.

CONTACT: Drew M. Kelley

PHONE: (303) 467-5236

Email: InvestorRelations@ArcGroupWorldwide.com

(GCAP) to Acquire City Index and Announces Record Preliminary Third Quarter Results

– Transaction creates global leader in FX/CFD trading, with over 235,000 funded accounts, $1.2 billion in customer assets and $3.1 trillion in annual trading volume – – Transaction adds significant scale to GAIN’s retail business – – Results in estimated operating synergies of $45 million-$55 million within two years – – Preliminary third quarter 2014 results include record revenues of $103 million, up 69% – – Adjusted EBITDA* of $26.6 million, up 120%; 26% adjusted EBITDA Margin* – – Net income of $14.7 million, or $0.32 per share, up from $5.6 million or $0.14 per share – (*See below for reconciliation of non-GAAP financial measures)

BEDMINSTER, N.J., Oct. 31, 2014  — GAIN Capital Holdings, Inc. (NYSE: GCAP, “GAIN”), today announced that it has entered into a definitive agreement to acquire City Index (Holdings) Limited (“City Index”), a leading online trading firm specializing in contracts-for-difference (CFDs), forex and UK spread betting, for approximately $118 million¹, or a net purchase price of $82 million, including $36 million in cash on the company’s balance sheet.

The combination of GAIN Capital and City Index creates a global leader in online trading, operating two market-leading brands in GAIN’s FOREX.com, a top retail forex brand globally, and City Index, a premier CFD and spread bet brand. The combined company will service 235,000 retail customers in over 180 countries with annual trading volumes of more than $3 trillion.

“The acquisition of City Index advances our growth strategy, creating scale for our retail business and accelerates the development of our innovative trading technology,” said Glenn Stevens, GAIN’s chief executive officer. “The combination will result in a balanced mix of customer volume, with approximately 61% of retail volume coming from FX and 39% from CFD trading/UK spread betting in other asset classes such as equities, indices and commodities. We look forward to leveraging the City Index brand in key markets and working with the team at City Index, who share our commitment to creating a superior customer experience.”

“This transaction is a landmark moment in City Index’s 30-year history as a leader in retail trading,” said Mark Preston, City Index’s Chairman and Chief Executive. “The combination of GAIN’s unrivalled leadership in global foreign exchange with City Index’s internationally-recognized CFD business creates a world-class industry leader, providing the scale and capability to deliver the ultimate trading experience to our clients around the world. The combined business will also offer greater opportunities for City Index’s management and staff to flourish in a global business.”

Founded in London in 1983 as one of UK’s first spread betting companies, City Index is today one of the world’s leading providers of CFDs, forex and UK spread betting, offering more than 10,000 products across equity, index, FX, commodity and bond CFDs and spread bets. City Index is majority owned by IPGL, the private holding company for the interests of Michael Spencer, Founder and Chief Executive of ICAP plc, the global markets operator.

“I am very pleased we have been able to agree to this transaction, which brings benefits for everyone,” said Michael Spencer. “I believe GAIN is an outstanding company and will be able to move City Index to the next level, by leveraging its broad array of trading products and services onto a global platform. We believe this combination will enhance GAIN’s leadership position in the FX/CFD industry by putting together two highly complementary companies to create significant value for customers and stakeholders. This is the latest example of the way that IPGL is able to invest actively in businesses over the long term to support their growth and development.”

For the 12 month period ended September 30, 2014, City Index generated $124.8 million in revenue and $10.7 million in adjusted EBITDA. It had approximately 104,000 funded retail accounts and $344 million in customer assets as of September 30, 2014.

The combined company will have pro forma client assets of approximately $1.2 billion, and trailing twelve month revenues and adjusted EBITDA, for the period ended September 30, 2014, of $462 million and $61 million, respectively. GAIN has identified $45 million – $55 million of fixed operating expense synergies, relative to the combined company’s trailing twelve-month expenses, and expects to begin realizing theses synergies promptly after closing with full integration achieved over the ensuing 18-24 months. GAIN expects for this acquisition to become highly accretive over this time period and anticipates achieving accretive results by the fourth quarter following closing.

The transaction follows the successful acquisition and integration of GFT, which closed in September 2013, where GAIN Capital achieved approximately $40 million of run rate expense synergies.

City Index clients will not see any immediate impact to the customer service they receive, their account administration or how they trade. All clients will receive more detailed information about the benefits the combined company can offer them, once the acquisition is completed.

Terms of the Transaction

The purchase price will consist of $20 million in cash, $60 million of convertible notes and the issuance of approximately 5.3 million GAIN shares. The total purchase price of $118 million represents a $28 million premium above City Index’s book value as of September 30, 2014.

In addition to the $36 million of cash on its books as of September 30, 2014, City Index also has $65 million of net operating losses which can be carried forward following the closing of the transaction.

The transaction is subject to approval by GAIN Capital stockholders, regulatory approvals and customary closing conditions. The deal is expected to close in the first quarter of 2015.

Jefferies LLC is serving as exclusive financial advisor to GAIN Capital. Keefe, Bruyette & Woods, A Stifel Company is serving as financial advisor to IPGL. Davis Polk & Wardwell advised GAIN Capital on U.S. and UK legal matters.  Macfarlanes advised IPGL and City Index on UK legal matters and Kirkland & Ellis advised IPGL and City Index on U.S. legal matters.

City Index Acquisition Conference Call

GAIN will host a conference call today, Friday, October 31, 2014 at 8.00 a.m. ET.  Participants may access the live call by dialing + 1-866-652-5200 (U.S. domestic), or + 1-412-317-6060 (international).

A live audio webcast of the call and a copy of the accompanying presentation will also be available on the Investor Relations section of the GAIN website (http://ir.gaincapital.com). A PDF copy of the presentation will also be available on the Investor Relations website.

An audio replay will be made available for one month starting approximately two hours after the call by dialing + 1-877-344-7529 in the U.S. or + 1-412-317-0088 from abroad, and entering passcode 10055502#

Preliminary Third Quarter Results

GAIN Capital also announced today preliminary results for the third quarter ended September 30, 2014. Net revenues for the third quarter ended September 30, 2014 were a record $102.8 million, an increase of 69% from $60.8 million from a year earlier. Adjusted EBITDA for the period was $26.6 million, an increase of 120% from $12.1 million from a year earlier. Net income was $14.7 million, or $0.32 per diluted share, up 163% from $5.6 million, or $0.14 per diluted share a year earlier. Cash earnings per share, which reflect earnings per share less the impact of depreciation and amortization, purchased intangible amortization and non-cash interest was $0.40 per diluted share, an increase of 124% from a year earlier. The Company will review its full third quarter results on Thursday November 6, 2014 during a conference call scheduled for 8:00 a.m. Details for the conference call with be forthcoming.

About GAIN Capital

GAIN Capital Holdings, Inc. (NYSE: GCAP) provides innovative trading technology and execution services to retail and institutional investors worldwide, with multiple access points to OTC markets and global exchanges across a wide range of asset classes, including foreign exchange, commodities, and global equities. GAIN Capital is headquartered in Bedminster, New Jersey, with a global presence across North America, Europe and the Asia Pacific regions. For further company information, visit www.gaincapital.com

About City Index

City Index (Holdings) Ltd. is a global provider of retail trading services including spread betting (UK only), CFDs and margin forex. Established in 1983, the firm trades primarily under the City Index, Finspreads, FX Solutions and IFX Markets brands with core markets in the UK, Middle East and the Asia Pacific.
For further company information, visit www.cityindex.co.uk

(*) Reconciliation of Net Income to Cash Net Income and Cash EPS

Cash net income is a non-GAAP financial measure and represents our net income excluding depreciation and amortization, purchased intangible amortization and non-cash interest expense. This non-GAAP financial measure has certain limitations, including that it does not have a standardized meaning and, therefore, our definition may be different from similar non-GAAP financial measures used by other companies and/or analysts. Thus, it may be more difficult to compare our financial performance to that of other companies. We believe our reporting of cash net income assists investors in evaluating our operating performance. However, because cash net income is not a measure of financial performance calculated in accordance with GAAP, such measure should be considered in addition to, but not as a substitute for, other measures of our financial performance reported in accordance with GAAP, such as net income.

Reconciliation of GAAP Net Income to Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is a non-GAAP financial measure that represents our earnings before interest, taxes, depreciation and amortization, restructuring, acquisition and integration-related expenses, impairment on investment and gain on extinguishment of debt. This non-GAAP financial measure has certain limitations, including that it does not have a standardized meaning and, therefore, our definition may be different from similar non-GAAP financial measures used by other companies and/or analysts. Thus, it may be more difficult to compare our financial performance to that of other companies. We believe our reporting of adjusted EBITDA assists investors in evaluating our operating performance. However, because adjusted EBITDA is not a measure of financial performance calculated in accordance with GAAP, such measure should be considered in addition to, but not as a substitute for, other measures of our financial performance reported in accordance with GAAP, such as net income.

Adjusted EBITDA Margin is adjusted EBITDA over net revenue.

Pro Forma Amounts

All pro forma amounts represent the combination of GAIN and City Index via simple addition.

Forward Looking Statements

The forward-looking statements contained herein include, without limitation, statements relating to GAIN Capital’s and/or City Index (Holdings) Limited (“City Index”) expectations regarding the opportunities and strengths of the combined company created by the proposed business combination, anticipated cost and revenue synergies, the strategic rationale for the proposed business combination, including expectations regarding product offerings, growth opportunities, value creation, and financial strength, and the timing of the closing.  All forward looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that GAIN Capital or City Index will realize these expectations or that these beliefs will prove correct. In addition, a variety of important factors could cause results to differ materially from such statements. These factors are noted throughout GAIN Capital’s annual report on Form 10-K, as filed with the Securities and Exchange Commission on March 17, 2014, and include, but are not limited to, the actions of both current and potential new competitors, fluctuations in market trading volumes, financial market volatility, evolving industry regulations, including changes in regulation of the futures companies, errors or malfunctions in GAIN Capital’s systems or technology, rapid changes in technology, effects of inflation, customer trading patterns, the success of our products and service offerings, our ability to continue to innovate and meet the demands of our customers for new or enhanced products, our ability to successfully integrate assets and companies we have acquired, our ability to effectively compete in the futures industry, changes in tax policy or accounting rules, fluctuations in foreign exchange rates and commodity prices, adverse changes or volatility in interest rates, as well as general economic, business, credit and financial market conditions, internationally or nationally, and our ability to continue paying a quarterly dividend in light of future financial performance and financing needs. The forward-looking statements included herein represent GAIN Capital’s views as of the date of this release. GAIN Capital undertakes no obligation to revise or update publicly any forward-looking statement for any reason unless required by law.

¹ The estimated total transaction value is based on the closing price of GAIN Capital common stock on October 30, 2014. The purchase price for accounting purposes will be determined upon the closing of the acquisition and will depend on GAIN Capital’s stock price at that time.

(ZYXI) Schedules Third Quarter 2014 Earnings Release and Webcast

(VTMB) Continues Double Digit Growth

(NSAV) Announces the Execution of a Due Diligence Evaluation

PORT JEFFERSON, NY, United States, via ETELIGIS INC., 10/31/2014 – – Net Savings Link, Inc. (OTC Pink: NSAV) (PINKSHEETS: NSAV) today has announced the execution of an agreement by our new President, Leonard F. Genovese, on behalf of NSAV, to conduct a formal due diligence evaluation for purposes of a targeted merger/acquisition with a well-established firm that has an entrenched and long term presence in the Artisanal food and beverage/wellness/ and retail distribution space in the Northeastern portion of the U.S., and is expanding nationally. Mr. Genovese commented; This is an exciting opportunity to pair the synergy of this firm with NSAV. The targeted firm has existing revenues with year over year growth for the past 3 fiscal terms, and has an established customer base that encompasses both a retail and institutional model. Mr. Genovese continued; The firm not only has a domestic presence, but also has a European base that brings significant product variety into existing domestic markets that we are optimistic to enter. They are a leader in imported foods from certain European markets, and they hold various proprietary food packaging agreements that will enhance product diversity. Mr. Genovese continued; we are optimistic that we will close on this agreement, pending the outcome of our D.D. evaluation, within the next 30-60 days.

Steven Baritz, the CEO of NSAV said, NSAV s recent decision to appoint Mr. Genovese has proven to already pay dividends in terms of corporate development, intermediate growth, and strategy. Mr. Genoveses mature contact base has expressed an eagerness to be a part of a firm that he is operating within a leadership capacity. Baritz continued, We are expressing extreme optimism that this will be the first of many strategic growth opportunities that Mr. Genovese will facilitate for NSAV, and we are certain that they will be well received by both the consumer as well as the shareholder and investor community. We will provide a subsequent update on the status of this announcement in a subsequent release upon the conclusion of the due diligence evaluation.

Mr. Baritz also commented on a recent concern of shareholders regarding the removal of the DTC chill; NSAV has made one of its top priorities, the removal of the DTC chill that has existed prior to the current management teams tenure on the Board. Baritz continued; It is apparent that in order for NSAV to move to the next level that will be commensurate with our intermediate and long term objectives, the removal of the chill will be of paramount importance, and we expect to commence the process to remove the chill as soon as certain self- imposed metrics are achieved in regard to capital availability and revenue expectations.

About Net Savings Link, Inc.:

Net Savings Link, Inc. owns and operates a wholly owned subsidiary, Global Distribution Corporation, a distribution company that markets and distributes products in varying industries including the supplement, wellness and natural remedies markets. People interested in learning more about Global Distribution should check back with the company at its website, www.Globaldistributioncorp.net.

DISCLAIMER: This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information contained in this Press Release including such forward-looking statements.

CONTACT:

David Pecoraro

Shareholder Relations Director

Email: DavidPecoraro@rocketmail.com

Tel: 814-418-6648

(YEWB) Applauds China State Forestry Admin’s Subsidy Of Medicinal Herb Crops

HARBIN, China, Oct. 30, 2014  — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber, today applauded the creation of a subsidy program by the State Forestry Administration of China to promote the development and growth of Chinese medicinal herb crops.

The central China government continues to increase financial support to the national forest economy in efforts to promote the proportion of investment in other sectors of planting, and to help forestry and growers become a new economic growth point. Heilongjiang Provincial Forestry Department, where Yew Bio-Pharm is located, was recently selected to receive initial subsidies for undergrowth planting of Chinese medicine herbs.

Under Heilongjiang Province’s Forest Economic Development Plan, which was announced in January 2014, the forest economy in the province is expected to reach 150 billion yuan (approximately US$24.5 billion) by 2020. The plan focuses on developing Chinese medicine, forest mushrooms, berries, vegetables, seeds and other undergrowth corps.

“As a leading yew tree grower in the region, and producer of traditional Chinese medicine used in certain cancer treatments, we are very encouraged by this positive development,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “The subsidies should help spur development of new projects and incentivize economic growth in the region for growers of traditional Chinese medicine crops.”

“With our advanced planting technologies, and one of the largest yew forests in China with more than 20,000 MU (approximately 3,300 acres), we are optimistic about the possibility of receiving the national financial support. Through this funding, we can further utilize the company’s 1 million MU (approximately 165,000 acres) of forestland to plant globally scarce anti-cancer medicine herbs,” Wang added.

ABOUT YEW BIO-PHARM GROUP, INC.

Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit http://www.yewbiopharm.com/.

(SWRF) Provides an Update on the Completion of SoOum Merger

New York, NY / October 30, 2014 / Swordfish Financial, Inc. (OTC:SWRF) provides a shareholder update regarding the process of the pending Swordfish/SoOum merger.

SWRF is pleased to report the final steps of the forthcoming merger with SoOum Corp. SWRF has contracted a leading provider in investor communications and financial printing, to distribute the information statement (Schedule 14f-1) as officially required as part of completing the merger. The printing has been completed and the mailing in process. The certification that this information statement is being delivered to shareholders of record, along with a FINRA filing, and final forms to the US SEC, enables closing. SWRF has been advised that final merger can occur in approximately fourteen (14) days.

SoOum CEO, William Westbrook, reported that, “The motivation, morale and vision of the entire upper management in SoOum is healthy and increasing. The merger with Swordfish, which is nearing its completion, fulfills SoOum’s demand for new talent, specialized experience, technology and market reaches.”

Luis Vega, SoOum’s, Chief Operation and Trade Officer, reports they have seen a significant increase in new trade opportunities due to the publicity it has received from its merger announcement, http://www.sooum.com/.

Also of note, in development news, SoOum has been working with Trade Risk Group (www.traderiskgroup.com) in attaining credit insurance for its top importers, thereby enabling the Company to offer a broader range of payment terms to its leading customers and enhancing its capacity to grow with less risk.

For further information regarding this release, contact Rich Kaiser, Business Consultant, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com.

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to matters such as prospects, anticipated operating and financial performance. Actual prospects and performance may differ from anticipated results due to economic conditions and other risks, uncertainties and circumstances partly or totally outside the control of the Company, including risks of market volatility, the level of capital expenditures required to fund ongoing trading operations and the ability of the Company to execute its business strategy. These and other risks are described in the Company’s reports filed with the United States Securities and Exchange Commission. These forward-looking statements are made only as of the date of this communication and the Company undertakes no obligation to update or revise these forward-looking statements.

Contact:
Rich Kaiser
757-306-6090
www.yesinternational.com

(OMER) Omidria™ Granted Pass-Through Reimbursement Status from CMS

— Unique Billing Code Allows Separate Payment for Omidria —

SEATTLE, Oct. 30, 2014  — Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria^™ (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Approved earlier this year by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement (ILR), Omidria is the only FDA-approved product for intraocular administration that prevents intraoperative miosis (pupil constriction) and reduces postoperative pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other ILR procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015.

Transitional pass-through status will allow ambulatory surgery centers and other outpatient facilities to bill Medicare and other insurance providers for Omidria using a temporary Healthcare Common Procedure Coding System (HCPCS) code unique to Omidria. Pass‑through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. Pass‑through remains in effect for a period of two to three years, after which time CMS and other insurance providers make a new reimbursement determination. Pass‑through status for Omidria will become effective on January 1, 2015, and reimbursement will be based on the product’s wholesale acquisition cost of between $400 and $500 per single-use vial.

“We are pleased with CMS’s decision to grant pass-through for Omidria,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Pass-through status should streamline the billing and reimbursement process for facilities that use Omidria and could accelerate adoption of the product across cataract and other intraocular lens procedures. Coincident with this new clarity on reimbursement, our commercial team is in the process of adding the second wave of sales representatives, and we plan to launch Omidria no later than early 2015.”

About Omidria^™
Omeros’ PharmacoSurgery^® product Omidria^™ (pronounced oh-MID-ree-uh) is a proprietary combination of the mydriatic (pupil-dilating) agent phenylephrine and the anti-inflammatory agent ketorolac, which was developed for use during cataract or other intraocular lens replacement (ILR) surgery. The FDA has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or ILR to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The European Medicines Agency (EMA) is currently reviewing the Marketing Authorization Application (MAA) for Omidria.

Important Risk Information for Omidria^™

Systemic exposure of phenylephrine may cause elevations in blood pressure. In clinical trials, the most common reported ocular adverse reactions at two to 24 percent are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Omidria^™ must be diluted prior to use. Omidria is not approved for use in children.

About Omeros Corporation

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery^® platform, the Company’s first drug product, Omidria^™ (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omeros is completing preparations for a planned U.S. product launch no later than early 2015. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros also has six clinical-stage development programs focused on complement-related thrombotic microangiopathies, Huntington’s disease, schizophrenia, and cognitive impairment; on addictive and compulsive disorders; and on preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with effectiveness of Omidria^™ sales and marketing efforts, Omidria market acceptance, product pricing and reimbursement, Omeros’ ability to obtain regulatory approval for its Marketing Authorization Application in the EU for the commercialization of Omidria, Omeros’ unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

(SUIP) Licensing Agreement for BreastCare DTS™ With LMT

BreastCare DTS(TM) Is Patented, Non-Invasive, FDA-Cleared Cancer Detection Device; Agreement Gives Sunrise Exclusive Distribution Rights in US, Canada, China

(CAPA) acquires the assets of Movie Star News, LLC

LOS ANGELES, Oct. 30, 2014 — Capital Art, Inc., a publicly traded company (CAPA), has announced that it has acquired the assets of Movie Star News, LLC. The Movie Star News archive is believed to be one of the largest and most comprehensive collections of original Hollywood photography and contains more than 100,000 negatives and over 1 million original studio photos, including photos of Marilyn Monroe, Audrey Hepburn, Cary Grant and other iconic Hollywood legends. In addition, the assets consist of the Irving Klaw archive of over 9,000 original camera negatives featuring Bettie Page. Bettie Page is considered by many to be the first pin-up model in history.

Movie Star News began in 1938 when photographer Irving Klaw struck a deal with the movie studios, then operating in New York City, to collect movie photography that was in great demand by Hollywood fans.  Klaw eventually began to create an archive of Hollywood studio original negatives from which prints were made for the media and adoring fans. The collection was moved to Las Vegas, Nevada in August 2012, and when the iconic store on West 18^th Street closed, it was hailed as the closing of a New York institution by many national publications.

Irving Klaw is credited for creating the world of pin-up photography. He extensively photographed Bettie Page, who came to be known as the “Queen of Pin-Ups.” The Bettie Page Collection includes over 5,000 negatives, photographs, clothing and other invaluable props.

Capital Art, Inc. sells limited edition, fine art Hollywood prints featuring the Frank Worth Archive, the Movie Star News Archive and the Bettie Page Collection. The company also makes photographs available for publication rights through its agreement with Getty Images.

(CDTI) Unveils Breakthrough Clean Air Technology

Initial patents awarded for vehicle exhaust-cleaning technology – Eliminates need for expensive platinum group and rare earth metals

OXNARD, Calif., Oct. 30, 2014  — Clean Diesel Technologies, Inc. (Nasdaq:CDTI) (“CDTi” or “the Company”), a leader in advanced emission control technology, announced the United States Patent and Trademark Office (USPTO) awarded it two new patents covering CDTi’s new technology that replaces costly platinum group and rare earth metals in catalytic converters. These patents represent the first of a family of patents for CDTi’s Spinel™ technology, a proprietary clean emissions exhaust technology that promises to dramatically reduce the cost of attaining more stringent clean air standards.

The new technology will power multiple catalytic product lines that the Company believes have the potential to be highly disruptive to the traditional platinum-based or rare earth-based device industry. This is the Company’s first public announcement regarding its Spinel technology, the development of which has been kept confidential until now.

CEO Chris Harris commented, “Currently global OEMs spend billions of dollars annually on platinum group metals (PGMs) mined in South Africa and Russia, and hundreds of millions of dollars on Chinese-sourced rare earth metals. These costs are expected to dramatically increase with conventional technology as new regulations like U.S. EPA Tier 3 kick in. Spinel technology solves a major industry supply and cost problem and marks a major breakthrough both for us and for all OEMs around the world manufacturing fossil fuel-powered engines.”

About Spinel Technology

• A family of proprietary materials using various base metals that replace costly PGMs and rare earth metals in coatings on standard catalytic converters
• Works across a wide range of engine and vehicle applications – both gasoline and diesel
• Advanced testing underway on production models of popular passenger cars and heavy duty vehicles at respected independent vehicle test facilities

Spinel Technology Significance and Benefits

• Potential for significant cost savings for OEMs by cutting out expensive PGMs and rare earth metals
• Currently OEMs spend over $6 billion a year on PGMs (source: derived from Johnson Matthey PLC: Platinum 2013 Interim Review)
• Enables early, cost-effective compliance with stricter emissions standards in the U.S. and around the world
• Mitigates OEM exposure to supply uncertainty and price volatility in the PGM and rare earth markets

CTO Dr. Stephen Golden added, “The Spinel technology is the result of hard work and ingenuity by our world-class R&D team. It is an entirely new materials science pathway to meeting tighter regulations at much lower cost. Key validation vehicle testing is underway in parallel with aggressively building a broad IP portfolio as we incorporate Spinel technology into specific products for global OEMs.”

For more information on CDTi’s Spinel technology, please visit www.cdti.com/spinel.

About CDTi

CDTi is a vertically integrated global manufacturer and distributor of emission control systems and products, focused on the light duty vehicle and heavy duty diesel markets. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology and other related technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. CDTi is headquartered in Oxnard, California and currently has operations in the U.S., the U.K., Canada, France, Japan and Sweden. For more information, please visit www.cdti.com.

About Platinum Groups Metals (PGMs)

Expensive PGM metals, which include platinum, palladium and rhodium, are used in the manufacture of emission control catalysts, with palladium and rhodium being the primary components used in catalysts serving the global light duty vehicle market. According to Johnson Matthey PLC’s “Platinum 2013 Interim Review,” in 2013, over 70% of all primary platinum and 80% of all primary rhodium produced originated in Southern Africa. Russia and Southern Africa combined supplied over 75% of palladium.

About Rare Earth Metals

Rare earth metals such as cerium, neodymium and lanthanum, also referred to as rare earth elements, are chemical elements used in many devices that people use every day, including computers, cell phones, rechargeable batteries and catalytic converters. As the global demand for these devices increases the use of rare earth metals is expected to rise. According to a 2014 U.S. Geological Survey Mineral Commodity Summary, the estimated value of refined rare earth metals imported by the U.S. in 2013 was $260 million. An estimated 79% of rare earth metals used in the U.S. were imported from China with 65% utilized in catalysts.

Forward-Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements. You can identify these forward-looking statements by the use of the words “believes”, “expects”, “anticipates”, “plans”, “may”, “will”, “would”, “intends”, “estimates”, and other similar expressions, whether in the negative or affirmative. Forward-looking statements are based on a series of expectations, assumptions, estimates and projections which involve substantial uncertainty and risk. In this document, the Company includes forward looking statements regarding the anticipated or potential benefits of Spinel™ technology, anticipated increases in OEM expenditures on PGMs and rare earth metals with conventional technology, the effects of new regulations, additions to CDTi’s IP portfolio in parallel with continued vehicle testing, the incorporation of Spinel™ technology into products for OEMs, and the effects of Spinel™ technology on the traditional platinum-based or rare-earth based device industry and demand for platinum group and rare earth metals. In general, actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including, but not limited, to (a) any inability by CDTi to (i) reduce costs; (ii) increase sales; (iii) realize benefits of investments; (iv) obtain sufficient funding; (v) realign its strategic path; (vi) execute its strategic priorities; (vii) commercialize its technology due to agreements with third parties; (viii) protect its intellectual property; (ix) obtain verifications, approvals or market acceptance of its products or technology; (x) attract or retain qualified personnel; (xi) achieve anticipated results; (b) changes in, lack of enforcement of or funding for emissions programs, regulations or standards; (c) competitive conditions; (d) fluctuations in or the stabilization of the prices of PGM and rare earth metals; (e) intellectual property infringement claims by third parties; (f) supply or delivery interruptions, limitations or failures; and (g) other risks and uncertainties discussed or referenced in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. In addition, any forward-looking statements represent the Company’s estimates only as of the date such statements are and should not be relied upon as representing the Company’s estimates as of any subsequent date. The Company specifically disclaims any obligation to update forward-looking statements. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

CONTACT: Becky Herrick or Cathy Mattison
         LHA (IR Agency)
         +1 415 433 3777
         bherrick@lhai.com
         cmattison@lhai.com

(MOST) Finalist in the 2014 NC Tech Awards, New Media/Digital Technology

The Company’s Groundbreaking Mobile App Development Technology and Customer Successes Have Qualified MobileSmith as a Finalist in North Carolina’s Prestigious Technology Awards Program

(FBCD) and COCO-AMO in Discussion With Distributors About Purchasing 3,500 Units

FBC and COCO-AMO Expanding Distribution With Partner Based on Retail Sales

(MHCC) Reports Record Third Quarter Revenue

Full Financial Results to Be Announced in Mid-November

(AMEH) Launches Apollo Palliative Services

GLENDALE, Calif., Oct. 29, 2014  — Apollo Medical Holdings, Inc. (ApolloMed) (OTC-QB: AMEH), an integrated physician-centric healthcare delivery company, today announced the launch of a new subsidiary, Apollo Palliative Services (APS), with the acquisition of majority stakes in both a hospice agency and a home health company.  In conjunction, the Company appointed Liviu Chindris, M.D., as President of APS.

APS will serve as a single source for hospice, palliative care and home health services for ApolloMed’s health plan, hospital and IPA clients in addition to its own subsidiaries and affiliated medical groups: ApolloMed ACO, Maverick Medical Group, AKM Medical Group, ApolloMed Care Clinics and ApolloMed Hospitalists.  The hospice agency serves three counties in Southern California, with an average daily census of 40-60 patients, while the home health agency services three counties in California with an average daily census of 100-140.

The hospice division of APS will serve terminally ill patients and their families through the use of an interdisciplinary team.  Depending on their needs, each hospice patient and their family is assigned a team comprised of a physician, nurse, home health aide, medical social worker, chaplain, dietary counselor and bereavement coordinator.  Hospice and palliative care services are provided in the patient’s home, assisted living/nursing home, or in a hospital.  The home health division will provide direct home skilled nursing and therapy services, as well as specialty programs such as disease management education, nutrition and help with daily living activities.

ApolloMed believes that several factors will contribute to the growth of its hospice and home health business: aging demographics, recognition that in-home services are significantly more cost-effective than institutional care, medical and technological advances that allow more healthcare procedures and monitoring to be provided at home and the benefits of recuperating from an illness or receiving care for a chronic condition in one’s own home.

“I am very excited to join the management team of ApolloMed as we launch Apollo Palliative Services,” stated Dr. Chindris.  “We understand the benefits of hospice, palliative care and home health services for patients and their families and our goal is to make APS one of the leading providers in Southern California.”

“The addition of hospice and home health services will enhance our integrated care model and provide a good platform for the expansion of APS.  We believe that as an efficient operator of integrated healthcare delivery, we are favorably positioned to benefit from current industry trends,” stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings.

“We are also very pleased to have Dr. Chindris, one of the earliest physicians to join HealthCare Partners, as a member of the ApolloMed team.  His wealth of knowledge and experience will be a tremendous asset as we continue to grow ApolloMed’s business and expand the services that we provide.”

Dr. Chindris earned his M.D. from the University of Medicine and Pharmacy in Cluj, Romania and completed an internship and residency in internal medicine at Brooklyn Hospital in Brooklyn, New York and Mercy Hospital in Buffalo, New York.  He has held memberships in the American College of Physicians and the American Academy of Hospice and Palliative Medicine.  He is fluent in Romanian, French, Italian, Spanish and English.  Dr. Chindris was a Senior Partner at HealthCare Partners before it was acquired by DaVita in 2012.

About Apollo Medical Holdings, Inc.
ApolloMed is a leading integrated physician-centric healthcare delivery company commited to providing exceptional multi-disciplinary care in the communities it serves.  ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups:  ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA),  ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit www.apollomed.net.

Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. (“the Company”).  In particular, when used in the preceding discussion, where we refer to quarter over quarter revenue growth targeted for the remainder of 2014 and the words “predicts,” “believes,” “expects,” “intends,” “seeks,” “estimates,” “plans,” “anticipates,” and similar conditional expressions or future or conditional verbs such as “will,” “may,” “might,” “should,” “would” and “could” are intended to identify forward-looking statements.  In addition, our representatives may from time to time make oral forward-looking statements.  Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management.  Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected.  Unknown or unpredictable factors also could have material adverse effects on the Company’s future results.  The forward-looking statements included herein are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements.  Accordingly, you should not place undue reliance on these forward-looking statements.  Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended January 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT
The Ruth Group
David Burke
646-536-7009 or via email at dburke@theruthgroup.com

(GRAS) Enters Into a Preliminary Agreement With SoFran

(SKVI) Appoints Network Marketing Expert Dean Aldridge as Master Distributor

Kintari Launching Patented Skin Care Product Line

(AMPG) Hiring of JP Fortune Group to Expand Operations, Shareholder Awareness

BOHEMIA, N.Y., Oct. 28, 2014 — AmpliTech Group, Inc. (OTCQB:AMPG) (“AmpliTech” or the “Company”), a trusted provider of RF/microwave, and low noise amplifiers for critical and high-reliability, wireless and commercial applications, is pleased to announce it has engaged JP Fortune Group. JPF is one of North America’s premier small-cap advisory firms. JP Fortune Group will assist the Company in capital structuring, debt management, M&A opportunities, development of a strategic advisory board, market positioning and shareholder communications. JPF will implement a comprehensive financial growth strategy and execute an extensive investor relations campaign. The company’s goal is to increase and exploit opportunity in the marketplace while maintaining a fair market value for its shareholders equity based on its unique technology and expertise.

“We are thrilled to partner with JPF to strengthen our financial operations while informing the investment community about our exciting company and its potential. It is just another step in the right direction with many more to follow,” said Fawad Maqbool, President & CEO of AmpliTech. “We are highly confident our combined efforts will garner successful results in a timely manner,” stated Larry Fortune of JP Fortune Group.

“We believe AmpliTech has developed a premier technology, and we are anxious to communicate the AMPG story to the investment community,” said James Moldenhauer, CEO of JPF.

Interested investors may contact James Moldenhauer at JPF at 714-420-2004.

About AmpliTech Group, Inc.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz – eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers’ own designs. Website: http://www.amplitechinc.com

About JP Fortune Group

JP Fortune Group; a Bryce Holdings, LLC brand is a premier independent investor relations and financial advisory firm, with the depth of experience and expertise to advise companies across a broad spectrum of industries, ranging in revenues from $5 million to over $500 million. With a combined management team experience exceeding 50 years, JP Fortune Group is a leader in providing the highest quality investor relations and financial consulting services for middle market companies across a wide spectrum of industries.

CONTACT: Fawad Maqbool
         CEO
         AmpliTech Group, Inc.
         631-521-7831

         Larry Fortune
         Managing Partner
         JP Fortune Group
         949-344-0539

(CPPXF) Posts 2014 Annual Results

VANCOUVER, British Columbia, Oct. 28, 2014  — Continental Energy Corporation (OTCQB: CPPXF) (the “Company“) an emerging international energy investment company with operations in Southeast Asia and Tanzania, Africa, today announced the filing on SEDAR of its audited consolidated financial statements for the year ended 30 June 2014. Complete copies of these financial statements are available for download from the SEDAR website at www.sedar.com.

The Company incurred a net loss of $939,489 during the 2014 fiscal year compared to a net loss of $700,115 during the prior year, an increase of $239,374. The increase in loss was primarily due to the operations of the Company’s Norwegian subsidiary, Visionaire Energy AS (“VEN“) and its two affiliated companies. The Company uses the equity method to account for its portion of the operations of these affiliates and recorded a loss of $311,972 during the 2014 fiscal year while in the prior year; the Company recorded an income of $37,143. The Company had a loss per share of $0.01 in both 2014 and 2013 fiscal years.

As announced on 16 September 2014, the Company agreed to sell its 51% interest in VEN for total consideration of US$1,200,000 to Visionaire Invest AS that owns the other 49% of VEN. The effective date of the sale is set in the agreement at 30 June 2014. The operations of VEN and its affiliates are therefore classified as discontinued operations held for sale. The Company’s investment in its Norwegian subsidiary was reflected at $862,375 on 30 June 2013 and the carrying value of the investment decreased to $559,068 by 30 June 2014.  The sale of VEN is subject to the approval from the shareholders of the Company at the Company’s annual general meeting scheduled for 5 December 2014.

As at 30 June 2014, the Company’s consolidated financial statements reflect a working capital deficit of $693,794. This represents a decrease in the working capital deficit of $50,898 compared to the 30 June 2013 working capital deficit of $744,692. Cash used in operating activities during the 2014 fiscal year totaled $533,013 compared to $189,464 in the prior year. The Company was able to generate more funds in the 2014 fiscal year and make the relevant payments towards its administrative costs. Cash from investing activities during the 2014 fiscal year was $1,219 whereas there was $15,544 expended on such activities during the prior year. Financing activities provided $42,948 in the 2013 fiscal year compared to $761,517 during the 2014 fiscal year primarily from a $750,000 loan that was converted to equity subsequent to 30 June 2014.

The Company also filed on SEDAR its annual reserves report for 2014 in the form referred to in Canadian National Instrument 51-101 “Standards of Disclosure for Oil and Gas Activities”. Complete copies of the reserves report are available for download from the SEDAR website, www.sedar.com.

On behalf of the Company,

Robert V. Rudman, C.A.
Chief Financial Officer

Further Info:  www.continentalenergy.com

No securities regulatory authority has either approved or disapproved the contents of this news release.

Forward Looking Statements – Any statements in this news release that are not historical or factual at the date of this release are forward looking statements. There are many factors which may cause actual performance and results to be substantially different from any plans or objectives described in any forward looking statements. Readers should also refer to the risk disclosures outlined in the Company’s regulatory disclosure documents filed with the Securities and Exchange Commission available at www.sec.gov. The Company assumes no obligation to update the information in this release.

(GNOLF) Division Signs Contract With Genoil to Build a $700M Refinery

Genoil Inc.
David K. Lifschultz
CEO
212 688 8868

(NSAV) Link Announces a Significant Addition to its Board of Directors

PORT JEFFERSON, NY, United States, via ETELIGIS INC., 10/28/2014 – – Net Savings Link, Inc. (OTC: Pink: NSAV) (PINKSHEETS: NSAV), today has announced a significant addition to its Executive Management Team and Board of Directors that will have a major impact on the continuing intermediate and long-term Corporate objectives that are being targeted by NSAV and Global Distribution Corp.

Steven Baritz, the CEO of NSAV said, NSAV is both pleased and proud to announce the appointment of Mr. Leonard Genovese as the President and Chairman of the Board of Net Savings Link, Inc. Mr. Genovese was a major figure in the family that built and operated the National chain of Genovese Drug Stores, Inc., one of the largest and most developed retail establishments in the United States. Mr. Genovese was the Vice President of Operations and Vice President of Marketing for the firm, which was sold to J.C. Penneys for $492 Million. During his tenure, the chain grew to 141 stores in NY, NJ, and CT, with over 5,000 employees, and when it was acquired by JC Penney, it had sales of over $800 Million at the time of acquisition. The stores were rebranded as Eckerd Drug Stores, and Rite Aid Drug Stores in NY, and are still operating and thriving today. Mr. Baritz continued; Mr. Genoveses decades of experience and contacts in the retail distribution sector are immense, especially within the wellness and food arenas, and are expected to create immeasurable opportunities and access for Net Savings Link and their subsidiaries, including our Nutra Horizon wellness product line along with other products that we are currently developing to bring to market. We are indeed fortunate to have him in a leadership capacity on our management team and Board of Directors. In fact, he is already engaged in discussions to generate revenues from both new product lines and access to distribution channels. Mr. Baritz continued; Included within his agreement with NSAV, Mr. Genovese has agreed to defer any salary until certain revenue metrics are attained, so that the company can minimize intermediate term expenses and concentrate on growth, access to distribution venues, and product development.

Mr. Baritz also provided an update on the Nutra Horizon wellness product line and its website. I am pleased to announce that our Nutra Horizon wellness product line has finished production and packaging, and is now available for release to the market. Mr. Baritz continued, It features NINE separate wellness products developed by our previously announced Oglethorpe Corp agreement, including a powerful Probiotic formulation that has a unique feature in that it can be taken in conjunction with some antibiotics , PRP Isolate Immune spray, 100% Colostrum formulation, Multiple flavors of concentrated vitamin and mineral compounds that have achieved observable results in the treatment of many illnesses, and received numerous user testimonials of the benefits. Mr. Baritz also commented on the Nutra Horizon website; Our Nutrahorizon website (www.Nutrahorizon.net) is officially open and features preliminary descriptions of the product line. The e-commerce portion of the site is still in its final development stage, and I expect the site to be fully complete and functional in terms of content, usability, and consumer access to purchase products within the next 30-45 business days. Mr. Baritz continued; We have already received strong positive feedback, along with many constructive suggestions from consumers and shareholders, and we are implementing those suggestions, including illustrations, detailed product information, and design changes into our refinements during the next 30-45 days of site development. At that time, consumers will be able to make purchases of the products directly from the website, which is expected to generate direct revenue to the company.

About Net Savings Link, Inc.

Net Savings Link, Inc. owns and operates a wholly owned subsidiary, Global Distribution Corporation, a distribution company that markets and distributes products in varying industries including the supplement, wellness and natural remedies markets. People interested in learning more about Global Distribution should check back with the company at its website, www.Globaldistributioncorp.net .

DISCLAIMER:

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information contained in this Press Release including such forward-looking statements.

CONTACT:

David Pecoraro,

Shareholder Relations Director

Email: DavidPecoraro@rocketmail.com

Tel : 814-418-6648

(ELRA) Wagering Exceeds $10M for the Month of October

NEW YORK, Oct. 28, 2014  — Elray Resources Inc. (OTCPK:ELRA) trading as Elray Gaming announced today that wagering in one of its JV Licensed Live Dealer Casino Facilities in Manila has already surpassed 10 Million USD for the month of October.

Brian Goodman, CEO stated that, “This is very encouraging as Elray has recently overcome some technical challenges in delivering the product into Asia and the encouraging and incremental wagering is as a result of the system now being stable and highly competitive in the world’s largest gaming arena – Asia. The expected yield of the live studio is around 2.5% of wagering and the facilities are highly scalable. Elray will shortly roll out additional Asian facing gaming products including a new fully integrated E-store and exclusive VIP club specifically targeting the Chinese market and in addition to gaming will also offer high ticket branded fashion and electronic items.”

www.ElrayGaming.com

About Elray

Elray is an established Gaming entity which owns and licenses Gaming Intellectual Property, Gaming Domains, Trademarks and Player Databases. Whilst Elray is a US company, we have a global presence with offices in London, South Africa, Sydney and Curacao, homes of the largest gaming operators, which helps us actively manage and serve our clients. Our sophisticated patented software automatically declines any gaming requests from within the United States, in strict compliance with current US law. Our Sydney office allows us to tap into skilled resources and some of the world’s largest client base, for regular, personal interaction. As our active operations are in a jurisdiction that is friendly to online gaming, our clients can rest assured that we are here to stay. www.elraygaming.com

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

CONTACT: Elray Gaming
         Email: info@elraygaming.com

(NNAN) Establishes ViralProtec Division to Supply Personal Protective Ebola Equipment

ViralProtec Announces Purchase Order With California Hospital

(NHMD) Announces It Has Agreed to Its Initial Contract to Sell Up To 100k Cans

Nate’s Food Co. Announces It Has Agreed to Its Initial Contract to Sell Up To 100,000 Cans

Los Angeles, California (FSCwire) – Nate’s Food Co. (OTC: NHMD) announced today that it has entered into an agreement to sell up to 100,000 cans.  The Company is currently finalizing the pricing and delivery date.

The agreement is with an on-line store and represents our initial contract.  Recently there has been an increase in on-line grocery delivery with companies such as Yummy.com, Amazon Fresh, Peapod.com and MaxDelivery.   These stores represent multi-channel delivery ability that did not exist for Batter Blaster and could significantly increase the Company’s number of distribution points.

The Company is continuing to have talks with grocery stores and big box stores regarding placing Nate’s Pancakes in the same stores that Batter Blaster was sold.

The Company will provide additional information once the contract has been finalized.

About Nate’s Food Co.

Nate’s Homemade pancake and waffle batter are a ready-to-use, pre-mixed pancake and waffle batter delivered in a pressurized can. Our pre-made batter makes light and airy pancakes or waffles that are fun for the entire family to make together, and are a great way to start your day. With no preparation and no clean-up, we’ve made making breakfast easier for your busy mornings.

Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual and interim reports.

Contacts:

Nate’s Food Co.

Nate Steck

(661) 418-7842

info@nhmd.net

(ALXA) and Ferrer Expand ADASUVE® Partnership

Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential Milestone Payments

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Oct. 27, 2014 — Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE^® (Staccato^® loxapine).  Ferrer is Alexza’s commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries (the Ferrer Territory). Ferrer and Alexza have agreed that Ferrer will purchase 2 million shares of Alexza common stock for $4.00 per share, thereby becoming the Company’s largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.

“Ferrer and Alexza’s collaboration has been focused on building the market for ADASUVE in our territory and a lasting relationship between the companies,” said Jordi Ramentol, Chief Executive Officer of Ferrer. “The expansion of our relationship with Alexza with this strategic investment demonstrates our belief in ADASUVE as a highly valuable therapy, something we also hear from physicians and patients who have had experience with this product. We are pleased to continue our work together to build ADASUVE into a global brand.”

“We have been very pleased with Ferrer’s commitment and progress in bringing ADASUVE to patients since the first country launch in Germany in the summer of 2013. In addition to ADASUVE now being available in nine EU countries, Ferrer has secured three ADASUVE approvals in Latin America,” said Thomas B. King, Alexza’s President and CEO. “We continue to see momentum in the uptake of ADASUVE and consistently hear from physicians about the clinical benefits that ADASUVE can convey to the patients they treat.”

King concluded, “We are excited Ferrer is making this strategic investment in Alexza, which reinforces Ferrer’s commitment to ADASUVE as an important new therapeutic and to the long-standing collaboration between our two companies.”

About ADASUVE (Staccato loxapine)
ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate    agitation in adult patients with schizophrenia or bipolar disorder. The EU marketing authorization for ADASUVE requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms. It also requires that ADASUVE be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side effects, such as bronchospasm.

Alexza and Ferrer estimate that as many as 8 million adults in the EU suffer from schizophrenia or bipolar disorder¹. Agitation is a common symptom for these patients², characterized by feelings of distress, anxiety and loss of control.

ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.

The authorization for ADASUVE in the EU differs from that in the United States, with respect to the indication statement, dose regimen, available dose strengths, and risk mitigation and management plans. For more information about ADASUVE, including the Summary of Product Characteristics and Patient Information Leaflet approved in the EU, please visit the EMA website. For the full prescribing information including boxed warnings for the U.S., please visit www.adasuve.com.

About Ferrer
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer’s human healthcare products are commercialized in more than 90 countries, through 27 international affiliates (including joint ventures) and 70 partners and distributors.

Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors. For more information, visit www.ferrer.com.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza’s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE is Alexza’s first commercial product, is based on the Staccato technology, and has been approved for sale by the U.S. Food and Drug Administration, the European Commission, and in Chile, Costa Rica and Guatemala.

Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza’s commercial partner for ADASUVE in the U.S. Ferrer is Alexza’s commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries. For more information, visit www.alexza.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
This news release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and its partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company’s capital to support the Company’s operations, and the Company’s ability to raise additional funds and the potential terms of such potential financings. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

References:
1. Wittchen H.U., et al., 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679.

2. Alexza data on file (primary market research among caregivers of patients with schizophrenia (95% have agitation) and bipolar patients (87% have agitation).

(PTRA) Hires Thompson Solutions, Technical Analysis At Sevier/Beaver Oil Project

Firm to Provide Initial Gravity and Magnetic Analysis at Sevier Oil Prospect

COLORADO SPRINGS, Colo., Oct. 27, 2014 — PetroTerra Corp. (OTCQB: PTRA) (“PetroTerra” or “the Company”), an independent oil and gas exploration company currently focused on the Sevier and Beaver Oil Project in west central Utah, announced today that it has engaged Thompson Solutions LLC (“Thompson”) to perform the next step in the technical analysis on the Company’s Sevier Oil Prospect.

“PetroTerra is excited to begin the development of its Sevier and Beaver Oil Project,” said John Barton, CEO of PetroTerra Corp. “By conducting an analysis of the gravity and magnetic data that already exists, and integrating the digital files and maps we receive from Thompson, this will aid us in identifying the most prospective trends and leads on our acreage and enable us to move to the second phase of development.”

PetroTerra Corp owns a 100% working interest and 80% net revenue interest in the Sevier and Beaver Oil Project, which is situated along the central Utah Thrust Belt. The Thrust Belt is a geologic feature that is part of an oil producing structural trend extending from Canada to the southern United States. The Company’s initial analysis will focus on the two Sevier County leases that comprise the Sevier Prospect.

Phase One Overview

Thompson will process both the public domain gravity and aeromagnetic datasets that currently exist over the Sevier Prospect. The public domain gravity data coverage is expected to be sufficient to identify major structures and geologic trends of interest. Integration of the gravity data with existing or to-be-acquired seismic will help to reduce interpretation ambiguities and to better characterize any potential risks as the project moves forward. The public domain aeromagnetic data will help delineate basement geologic structure and faulting that can impact migration and trapping of hydrocarbons in the overlying sedimentary section.

When processing of the public domain gravity and aeromagnetic data is complete, Thompson will provide PetroTerra with digitally enhanced files and maps.  Analysis of these products will help PetroTerra focus on prospective trends and leads in the area.  Based on the results of this analysis, a new detailed land gravity survey, and possibly a new high resolution aeromagnetic survey, will be considered for Phase Two.

About PetroTerra Corp.

PetroTerra Corp. (OTCQB: PTRA) is an independent oil and gas exploration company based in Colorado Springs, Colorado. The Company is engaged in identifying, evaluating and developing early stage onshore oil and gas opportunities in the domestic US. The Company’s strategy is to focus on a step-by-step approach to assets that are located in high potential, proven basins and to prudently develop and manage those assets to create maximum value for shareholders. The Company’s current focus is on the Sevier and Beaver Oil Project in west central Utah. The Company owns a 100% working interest and 80% net revenue interest in the project.

To learn more about PetroTerra Corp. please visit http://www.petroterracorp.com/.

About Thompson Solutions LLC

Thompson Solutions LLC provides integrated geophysical and geological interpretation solutions for the exploration of oil, gas, and minerals. They provide custom solutions that are based on integration of the client’s data with Thompson’s expertise in the interpretation of gravity, magnetic, and geological data.

Thompson Solutions was founded by Gary Thompson, a senior geophysicist and geologist with over 30 years worldwide experience with potential field geophysics, exploration geology, and Geographic Information Systems (GIS). His industry training and experience includes time with Unocal Corporation and the Superior Oil Company.

Cautionary Statement Regarding Forward Looking Information

This press release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These statements include statements about our plans, strategies, financial performance, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by PetroTerra and its management team, are inherently uncertain. A more complete description of these risks and uncertainties can be found in our filings with the U.S. Securities and Exchange Commission. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

PetroTerra Corp.
422 East Vermijo Avenue
Suite 313
Colorado Springs, Colo. 80903
Tel: 719-219-6404
Fax: 719-219-6200

Investor Relations Contact
KCSA Strategic Communications
880 Third Avenue
New York, NY 10022
Brad Nelson / Jeffrey Goldberger
Toll Free:  1-800-787-2062
Email: ir@petroterracorp.com

(HPTG) Installation of HydroPlant on MPK Public Transportation Buses in Poland

Water-Based Hydrogen Fuel Production Systems Designed to Improve Fuel Efficiency and Reduce Greenhouse Gas Emissions

(RCPT) Positive P2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis

– Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment –

–   Safety data are consistent with the favorable profile observed in Phase 2 trial in relapsing multiple sclerosis –

–    Receptos plans to initiate Phase 3 program in ulcerative colitis and Phase 2 program in Crohn’s disease –

–   Investor conference call and webcast today at 5:00 p.m. ET (2:00 p.m. PT) –

SAN DIEGO, Oct. 27, 2014  — Receptos, Inc. (Nasdaq:RCPT) today announced that TOUCHSTONE, the Phase 2 trial of RPC1063 in ulcerative colitis (UC), met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1 mg dose of RPC1063 in the 8-week induction period. The overall safety and tolerability profile of RPC1063 was consistent with the results of the recent Phase 2 trial in relapsing multiple sclerosis (RMS), and continues to support the potential for orally administered RPC1063 to significantly improve the treatment paradigm for UC patients. The maintenance period of the TOUCHSTONE trial is currently ongoing.

This randomized, double-blind, placebo-controlled trial assessed the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of RPC1063 in patients with UC across 57 sites in 13 countries. The trial enrolled 199 patients, approximately 10% higher than planned, due to a strong interest among investigators and patients to participate in the study. The primary endpoint of the trial, the proportion of patients in clinical remission at week 8 as defined by the industry standard Mayo scoring criteria, was achieved by 16.4% of patients on the 1 mg dose of RPC1063, as compared to 6.2% of patients on placebo, which was statistically significant (p<0.05). In the low dose group of 0.5 mg, 13.8% of patients achieved clinical remission, which was not statistically significantly different from the placebo group.

All secondary endpoints at week 8, including clinical response, change in the Mayo score and mucosal improvement on endoscopy were also positive and statistically significant for the 1 mg dose. Notably, 58.2% of patients on the 1 mg dose of RPC1063 achieved clinical response, as compared to 36.9% of patients on placebo (p<0.05). Trends were observed for all secondary efficacy endpoints for the 0.5 mg dose group that appear to demonstrate evidence of a dose response. The detailed results of the Phase 2 portion of the TOUCHSTONE trial are expected to be presented at a major scientific meeting in the coming months.

RPC1063 was generally well tolerated, and the incidence of adverse events across the active treatment groups and placebo appeared to be similar. Most adverse events were either mild or moderate in nature, and there appeared to be no concerning signals in the adverse events of special interest, including the cardiac and hepatic safety profiles. With regard to the cardiovascular profile, first dose mean changes in heart rate in patients receiving RPC1063 were generally modest during the first six hours after administration, which is consistent with the findings of the earlier Phase 2 trial in RMS and thorough QT study. Rates of liver transaminase elevations observed in patients receiving RPC1063 were low and consistent with the earlier Phase 2 trial in RMS.

“The results of this trial demonstrated a significant treatment effect of orally administered RPC1063 at the 1 mg dose, with what appears to be a clear dose response and consistency across both the primary and secondary efficacy endpoints,” said Dr. William Sandborn, M.D., Professor of Medicine and Chief, Division of Gastroenterology and Director, University of California San Diego Inflammatory Bowel Disease Center. “The results also showed a favorable overall safety profile. A Phase 3 program is clearly warranted in order to confirm and extend these results.”

Based on these results, Receptos plans to initiate a Phase 3 program in 2015 to compare the safety and efficacy of the 1 mg dose of RPC1063 to placebo in patients with UC. In addition, these results suggest the potential for RPC1063 to be used in the treatment of Crohn’s disease, a related inflammatory bowel disease. Receptos plans to initiate a Phase 2 study of RPC1063 for the treatment of Crohn’s disease in 2015.

“The positive results of the TOUCHSTONE study exceeded our expectations with respect to the treatment effect of RPC1063,” said Faheem Hasnain, President and Chief Executive Officer of Receptos. “The consistency of the efficacy data across the various endpoints for the high dose, combined with the favorable safety profile, gives us confidence to move forward expeditiously with Phase 3 trials in ulcerative colitis and a Phase 2 trial in Crohn’s disease. There is a tremendous unmet need for a novel orally administered therapy in these patient populations. In addition, we believe that RPC1063 may have promise in other therapeutic areas, and we intend to continue to explore other autoimmune indications where RPC1063 may provide utility.”

Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) 

The Receptos management team will host a teleconference and webcast to discuss the information in this press release. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), conference ID 26817792. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 26817792.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company’s lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI).

About TOUCHSTONE

TOUCHSTONE is a randomized, double-blind, placebo-controlled Phase 2 trial investigating the effect of two orally administered doses of RPC1063 versus placebo in patients with moderately to severely active ulcerative colitis. This trial enrolled 199 patients across 57 sites in North America, Europe and Asia Pacific. The trial consists of an 8-week induction period followed by a blinded 24-week maintenance period for patients achieving clinical response during the induction period.  The maintenance portion of the trial is ongoing and is expected to be completed in 2015. Additional information regarding TOUCHSTONE is available at www.clinicaltrials.gov (NCT01647516).

Forward-Looking Statements

Statements contained in this release, other than statements of historical fact, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “expects,” “believes,” “may,” “intends,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as RPC1063 constitute forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation consistency of trial results to date with further trial results, the Company’s ability to adequately and timely recruit and enroll patients in its clinical trials, as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company’s SEC filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2014 and June 30, 2014. All forward-looking statements contained in this release speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@receptos.com

(VTAE) Exercise of Underwriters’ Option to Purchase Additional IPO Shares

FORT WASHINGTON, Pa., Oct. 27, 2014  — Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.

Stifel and BMO Capital Markets acted as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences acted as co-managers for the IPO.

A copy of the final prospectus related to the IPO may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Telephone: (415) 364-2720, email: syndprospectus@stifel.com; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 27^th Floor, New York, NY 10036, Telephone: (800) 414-3627, email: bmoprospectus@bmo.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

CONTACT: Investors:
         Vitae Pharmaceuticals, Inc.
         Richard S. Morris, CPA
         Chief Financial Officer
         (215) 461-2000
         rmorris@vitaerx.com

         Westwicke Partners
         John Woolford
         (443) 213-0506
         john.woolford@westwicke.com

         or

         Media:
         6 Degrees PR
         Tony Plohoros
         (908) 940-0135
         tplohoros@6degreespr.com